The overall pharma market grew at the forecast compound annual growth rate (CAGR) of 4.7% from 2020–2026, with small molecules and biotech products contributing 43.7% and 30.2%, respectively, to total revenue. Biotech products are expected to drive the growth of the pharma market faster (8.2%) than small molecules (3.0%) between 2020 and 2026. Monoclonal antibodies (Ab) are expected to contribute more than 50% to the biotech product segment.

A biobank is a facility involved in the collection, preservation, processing, storage, and supply of biological biospecimens and associated data, which follows standardized operating procedures and provides biospecimen for scientific and clinical use. For the purpose of analysis, the biobank market is segmented into specimen type, type of biobank, ownership, application, end user and region. The market study provides the dynamics and trends of the global biobanking market. It offers market estimations and forecasts for the biobanking services such as collection, preservation, processing, storage, and distribution. However, it excludes the revenue generated from the equipment, consumables, and software used in biobanks along with revenue generated from environmental repositories services.

The study assesses various trends (economic, product, technology) influencing the global centrifugal pump market. This includes a quantitative assessment comprising product segments, end users, and geography, and a competitive assessment. It also highlights overall market growth prospects over the next five years. The study segments the centrifugal pump market into single stage, multi-stage, axial and mixed flow, submersible, and sealless and circulator pumps.

When one company failed, it joined the other to accelerate the development and manufacture of a successful vaccine. Governments, retail pharmacies, health systems, payers, and nonprofits are working together to provide widespread distribution and administration.

Amid the tragic consequences of COVID-19, life sciences and medtech companies emerged as lights in the darkness. Decades of scientific work and investment seemed to be overnight successes. The heroic dedication of health care providers was met by the fastest novel vaccine development in history. Traditional competitors partnered to accelerate research and manufacturing.

Amid the tragic consequences of COVID-19, life sciences and medtech companies emerged as lights in the darkness. Decades of scientific work and investment seemed to be overnight successes. The heroic dedication of health care providers was met by the fastest novel vaccine development in history. Traditional competitors partnered to accelerate research and manufacturing. When one company failed, it joined the other to accelerate the development and manufacture of a successful vaccine. Governments, retail pharmacies, health systems, payers, and nonprofits are working together to provide widespread distribution and administration.